Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 46 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3% Hypertonic saline Clear all

Conditions: Water Stress, Body Water Dehydration
Interventions: Hypertonic Saline, Normal Saline; Other
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Brain Concussion, Post-Concussion Symptoms
Interventions: 3% Hypertonic saline, Placebo; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 6 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rhinovirus
Interventions: Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care; Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Bronchiolitis
Interventions: Nebulized 3% saline, Nebulized 0.9% saline; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 24 Months
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Oakland, California

Conditions: Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions: Nitric Oxide; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Tolvaptan, Hypertonic saline infusion; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Subdural Hematoma
Interventions: Dextrose 5% W/ Sodium Chloride 0.225%; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Cystic Fibrosis
Interventions: VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more

Conditions: Bronchiolitis, Viral, Saline Solution, Hypertonic
Interventions: Nebulized 3% saline, Nebulized 0.9% Normal Saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 23 Months
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Respiratory Failure
Interventions: Hypertonic saline (3%), Placebo (0.9% saline); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Shock, Traumatic
Interventions: 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more

Conditions: Head Injury, Minor, Pediatric, Emergency Department Patient
Interventions: Hypertonic Saline ( 3% Sodium Chloride Saline), Normal Saline (0.9% NaCl); Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 8 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bronchiolitis
Interventions: 3% sodium chloride, 0.9% sodium chloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 12 Months
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cystic Fibrosis
Interventions: Xylitol, Hypertonic saline; Drug
Lead sponsor: Joseph Zabner; Other
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Moderate to Severe Asthma
Interventions: 3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol; Device · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: 23.4% Hypertonic saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Injuries, Traumatic
Interventions: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD), 7.5% Hypertonic Saline (HS), 0.9% Normal Saline (NS); Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 7 more

Conditions: Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions: Hypertonic saline, Azithromycin, Ethambutol, Rifampin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: New York, New York • Portland, Oregon

Conditions: Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions: Nebulized hypertonic saline; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hyponatremia Symptomatic, Osmotic Demyelination Syndrome, Cerebral Edema
Interventions: Hypertonic 3% saline; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Bronchiolitis
Interventions: 3% Hypertonic Saline, 0.9 % normal saline; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Months to 12 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

Use of Salt-Water Solution to Improve Symptoms in Concussion

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

Nebulized Hypertonic Saline for Bronchiolitis

Vascular ARDS Recruitment After Inhaled Nitric Oxide

Effects of Tolvaptan in Healthy Adults

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Hypertonic Saline for Acute Bronchiolitis

Nebulized Hypertonic Saline for Mechanically Ventilated Children

Hypertonic Resuscitation Following Traumatic Injury

Hypertonic Saline for Mild TBI in Pediatric Patients

A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis

Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

Hypertonic Saline for MAC

Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury

International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis